A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China

[1] Zeiser R(2017)Pathophysiology of chronic graft-versus-host disease and therapeutic targets N Engl J Med 377 2565-79

[2] Blazar BR(2016)Risk factors and outcome of chronic graft-versus-host disease after allogeneic stem cell transplantation-results from a single-center observational study Biol Blood Marrow Transplant 22 1781-91

[3] Grube M(2012)Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go J Hematol Oncol 5 10-15

[4] Holler E(2015)How we treat chronic graft-versus-host disease Blood 125 606-9

[5] Weber D(2016)ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings Sci Signal 9 ra73-54

[6] Holler B(2014)Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism Proc Natl Acad Sci U S A 111 16814-89

[7] Herr W(2021)ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease Clin Immunol 230 108823-92

[8] Wolff D(2016)Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism Blood 127 2144-99

[9] Lv M(2021)Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar study Blood 138 2278-58

[10] Huang XJ(2022)FDA Approval Summary: Belumosudil for adult and pediatric patients 12 years and older with chronic GvHD after two or more prior lines of systemic therapy Clin Cancer Res 28 2488-38

[1] Zeiser R(2017)Pathophysiology of chronic graft-versus-host disease and therapeutic targets N Engl J Med 377 2565-79

[2] Blazar BR(2016)Risk factors and outcome of chronic graft-versus-host disease after allogeneic stem cell transplantation-results from a single-center observational study Biol Blood Marrow Transplant 22 1781-91

[3] Grube M(2012)Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go J Hematol Oncol 5 10-15

[4] Holler E(2015)How we treat chronic graft-versus-host disease Blood 125 606-9

[5] Weber D(2016)ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings Sci Signal 9 ra73-54

[6] Holler B(2014)Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism Proc Natl Acad Sci U S A 111 16814-89

[7] Herr W(2021)ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease Clin Immunol 230 108823-92

[8] Wolff D(2016)Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism Blood 127 2144-99

[9] Lv M(2021)Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar study Blood 138 2278-58

[10] Huang XJ(2022)FDA Approval Summary: Belumosudil for adult and pediatric patients 12 years and older with chronic GvHD after two or more prior lines of systemic therapy Clin Cancer Res 28 2488-38